Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.36 |
| ▸ | PRKCI | P41743 | 5/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.34 |
| ▸ | GALR2 | O43603 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119695 | 0.85 | CYP2A6 (0.50) | MAPTRAB9AADORA2AADORA1NPC1 | |
| SCHEMBL8336344 | 0.84 | MEN1 (0.39) | MAPTRAB9ANPC1PDE4BPDE4D | |
| SCHEMBL5815431 | 0.83 | PTGS2 (0.43) | MAPTPRKCIPDE4BPDE4DALDH1A1 | |
| SCHEMBL7521883 | 0.82 | KDM4E (0.53) | MAPTRAB9AADORA2AADORA1NPC1 | |
| SCHEMBL7513372 | 0.81 | PDE5A (0.55) | MAPTABCG2PRKCIPDE4BPDE4D | |
| SCHEMBL8178691 | 0.80 | MAPT (0.40) | MAPTRAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL5123556 | 0.79 | ADORA2A (0.42) | MAPTRAB9AADORA2AADORA1NPC1 | |
| SCHEMBL5129642 | 0.79 | ADORA2A (0.40) | MAPTRAB9AADORA2AADORA1NPC1 | |
| SCHEMBL5116143 | 0.79 | METAP1 (0.49) | MAPTRAB9AADORA2AADORA1NPC1 | |
| SCHEMBL7516851 | 0.77 | PRKCI (0.41) | MAPTADORA2AADORA1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | MAPT 2997/4885RAB9A 3220/4885AHR 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.